原名「台灣學術線上」
包含TAO期刊庫 + TAO書籍庫 + 論文 + 史料文獻
首頁 | 關於TAO | 瀏覽 | 進階查詢 | 參考工具 | 會員服務 | 已購專書 | RSS服務 | 電子報 | FAQ  
查詢範圍:
   
查詢模式:
熱門查詢詞:
dvd網咖消費者顧客滿意度資優生world
   
   
   
     
   
 
項次 書目
1
題名:TRANSURETHRAL RESECTION OF BLADDER TUMORS FOLLOWED BY RADIOTHERAPY WITH OR WITHOUT CHEMOTHERAPY FOR BLADDER PRESERVATION IN PATIENTS WITH INVASIVE BLADDER TRANSITIONAL CELL CARCINOMA: PRELIMINARY NTUH EXPERIENCE     (28點)
經尿道膀胱腫瘤切除術後之放射治療有無合併化學治療用於膀胱癌病患之膀胱保留療法:初步報告
著者:Feng-Ming Hsu(許峰銘) ;Jason Chia-Hsien Cheng(成佳憲) ;Yeong-Shian Pu(蒲永孝) ;Chia-Chi Lin(林家齊) ;Ming-Kuen Lai(賴明坤)
出版地區:台灣
出版城市:台北市
學科:醫學綜合
關鍵字:膀胱癌 ; 保留療法 ; 三合一治療 ; Bladder cancer ; Preservation ; Trimodality therapy
刊名:Therapeutic Radiology and Oncology
頁碼:103-116
語言:英語
摘要: 中文摘要PDF ; 英文摘要PDF

且且:根除性膀腕切除術是侵襲性膀恍轉型細胞癌的標準治療方式。經尿道膀脫腫瘤切除術合併放射治療提供膀腕切除術之外,保留膀忱的治療選擇。加上前導性及同時性化學治療之三合一療法能進一步改善治療成效。本篇研究報告將評估三合一療法用於膀脫保留療法之短期成效及治療相關之副作用。 材料與芳:圭:本研究收集2000 至2004 年, 37 位罹患膀耽轉型細胞癌且接受膀耽保留療法之病人進行回顧分析。其中21 位病人只接受經尿道膀脫腫瘤切除術合併放射治療。其餘16 位病人在接受經尿道膀脫腫瘤切除術與前導性化學治療後達到完全或部份緩解之後,接受進一步之放射治療或同時性化學治療合併放射治療。在三合一治療組中,放射治療之設計為每天一次1. 8Gy' 治療劑量為:骨盆腔的Gy' 全膀眛50 .4 Gy ,腫瘤部位64.8 Gy 。未接受化學治療之病人接受之每天一次2.0 Gy 之放射治療,治療劑量為:骨盆腔的Gy' 全膀眛60 Gy 0 接受三合一治療之病人在療程中須接受膀脫鏡檢查以確定是否持續達到完全緩解,得以繼續放射治療之療程。 鐘星:三合一療法組病人之中位年齡為6 1. 8 歲,只接受放射治療組中位年齡為76.8 歲。全體病人共有30 位男性'7 位女性。在三合一治療組中,有14 位病人在經尿道膀耽腫瘤切除術與前導性化學治療後達到完全緩解。有7 位病人發生第三或第四級急性反應,其中2 位因治療毒性而死亡o 另外5 位在調整化學治療處方後繼續完成療程。只接受放射治療組中則只有1 位病人發生第三級急性反應。中位追蹤時間在三合一療法組為14.6 個月,只接受放射治療組為21 個月。一年局部控制率在三合一療法組為93.3% '只接受放射治療組為72.0% (p 值0.11 )。三合一療法組與只接受放射治療組之一年遠端轉移控制率,疾病控制率與存活率分別為100% 與73.3%(p 值0.047) , 93.3% 與62.3% (p 值0.05) ,以及87.5% 與79.8% (p 值0.23 )。 益益:在增加急性反應之代價之下,三合一膀恍保留療法提供較佳之遠端轉移控制率與傾向有較好的疾病控制率。本院目前所使用的療程似乎具有可行性且可為多數病人所承受。在有限的短期之追蹤下,三合一膀恍保留療法之成效在部份病人有令人滿意的成果。但仍須更長時間的追蹤來確認此保留療法的最終成果。
Purpose : Radical cystectomy has been the standard treatment for invasive transitional cell carcinoma (TCC) of urinary bladder. Transurethral resection of bladder tumors (TUR-BT) and radiotherapy (RT) provide an alternative option to cystectomy for organ preservation. The trimodality therapy (TMT) incorporating neoadjuvant and concurrent chemotherapy (CHT) seems to improve the treatment result. This study is to evaluate the short-term outcome and treatment-related toxicity of the TMT for bladder preservation. Materials and Methods : From 2000 to 2004, 37 patients with invasive bladder TCC undergoing bladder preservation therapy were reviewed retrospectively. Among them, 21 patients received radical TUR-BT followed by RT alone. The other 16 patients who had complete response or good partial response after radical TUR-BT and neoadjuvant CHT received further RT or concurrent chemoradiation. The RT protocol was 45 Gy to small pelvis field and 50.4 Gy to whole bladder, plus tumor bed boost to a total dose of 64.8 Gy with daily fraction size of 1.8 Gy in the TMT group. Patients in the RT alone group received 60 Gy to whole bladder or 40 Gy to whole pelvis plus 20 Gy boost to whole bladder with daily fraction size of 2.0 Gy. Interval cystoscopy was performed to confirm the status of complete response for continuation of RT in the TMT group. Results : The median age was 61.8 in the TMT group and 76.8 in the RT alone group. Thirty patients were male and seven were female. In the TMT group, fourteen patients had complete response after radical TUR-BT and induction CHT. Seven patients (43.7%) in the TMT group had grade 3 or 4 acute toxicity, and two of them died of treatment toxicity. The other five patients completed their treatment course with modification of CHT. In the RT alone group, only one patient (4.7%) had grade 3 acute toxicity. The median follow-up was 14.6 months in the TMT group and 21 months in the RT alone group. In the 14 patients completing TMT, two patients experienced local recurrence and none of 16 patients had distant metastasis. In the RT alone group, eight of 21 patients had local recurrence while 7 patients had distant metastasis. The one-year locoregional control rates were 93.3% in TMT group and 72.0% in RT alone group (p = 0.11). The one-year metastasis-free survival, disease-free survival, and overall survival were 100% and 73.3% (p = 0.047), 93.3% and 62.3% (p = 0.05), and 87.5% and 79.8% (p = 0.23), respectively. Conclusion : At the cost of increased acute toxicity, TMT for bladder preservation provides significant better metastasis-free survival and favorable disease-free survival. Our protocol seems feasible and well tolerated in most patients. With limited follow-up, the result of TMT remains satisfactory in selected patients. Longer observation is needed to confirm the ultimate success of bladder preservation.


    

本卷期目次
Therapeutic Radiology and Oncology
Side Effects of Amifostine with Concurrent Chemoradiation Therapy for Head and Neck Cancer/ Chien-An ChenChen-His HsiehYuen-Liang LaiMoon-Sing LeeYuen-Jen ChenShih-Kai Hung
Transurethral Resection of Bladder Tumors Followed by Radiotherapy with or without Chemotherapy for Bladder Preservation in Patients with Invasive Bladder Transitional Cell Carcinoma: Preliminary Ntuh/ Feng-Ming HsuJason Chia-Hsien ChengYeong-Shian PuChia-Chi LinMing-Kuen Lai
IMRT for a Malignant Mesothelioma/ Chi-Yuan YehPerng-An LaiKuang-Wei HuangChiu-Ping ChenJo-Ting Tsai
Prognostic Factors Affecting the Outcome of Endometrial Cancer/ Chu-Ping PiMu-Tai LiuJui-Chang HsuChia-Chun HuangTung-Hao ChangAi-Yih WangWen-Shan LiuChao-Yuan Huang
Scalp Metastasis from Transitional Cell Carcinoma of Renal Pelvis-A Case Report and Review of the Literature/ Hsi-Sheng ChsiaWen-Lin HsuYung-Hsiang HsuHann-Chorng KuoDai-Wei LiuMoon-Sing LeeEn-Lin TsaiMing-Hsiang Chu
Adjuvant Concurrent Uracil-Tegafur with Leucovorin and Radiotherapy for Locally Advanced Rectal Cancer/ Chen-Hsi HsiehTzu-Chi HsuYu-Jen ChenHsi-Hsien HsuChien-Kuo LiuShih-Kai HungYuen-Liang LaiHong-Wen ChenKou-Hwa Chang
Radiobiological Characterization of the Epithermal Neutron Beam Produced at the Tsing Hua Open-Pool Reactor (THOR) for BNCT: Comparison with Other BNCT Facilities/ John GueuletteHong-Ming LiuShiang-Huei JiangHsueh Yen-Wan LiuBlanche-Marie De CosterYuan-Hao LiuWen-Chyi TsaiAndré WambersieAng-Yu Chen
TRANSURETHRAL RESECTION OF BLADDER TUMORS FOLLOWED BY RADIOTHERAPY WITH OR WITHOUT CHEMOTHERAPY FOR BLADDER PRESERVATION IN PATIENTS WITH INVASIVE BLADDER TRANSITIONAL CELL CARCINOMA: PRELIMINARY NTUH EXPERIENCE/ Feng-Ming HsuJason Chia-Hsien ChengYeong-Shian PuChia-Chi LinMing-Kuen Lai
ADJUVANT CONCURRENT URACIL-TEGAFUR WITH LEUCOVORIN AND RADIOTHERAPY FOR LOCALLY ADVANCED RECTAL CANCER/ Chen-Hsi HsiehTzu-Chi HsuYu-Jen ChenHsi-Hsien HsuChien-Kuo LiuShih-Kai HungYuen-Liang LaiHong-Wen ChenKou-Hwa Chang
SIDE EFFECTS OF AMIFOSTINE WITH CONCURRENT CHEMORADIATION THERAPY FOR HEAD AND NECK CANCER/ Chien-An ChenChen-His HsiehYuen-Liang LaiMoon-Sing LeeYuen-Jen ChenShih-Kai Hung
RADIOBIOLOGICAL CHARACTERIZATION OF THE EPITHERMAL NEUTRON BEAM PRODUCED AT THE TSING HUA OPEN-POOL REACTOR (THOR) FOR BNCT: COMPARISON WITH OTHER BNCT FACILITIES/ Hong-Ming LiuShiang-Huei JiangYen-Wan Hsueh LiuYuan-Hao LiuWen-Chyi TsaiAng-Yu Chen
SCALP METASTASIS FROM TRANSITIONAL CELL CARCINOMA OF RENAL PELVIS-A CASE REPORT AND REVIEW OF THE LITERATURE/ Hsi-Sheng ChsiaWen-Lin HsuYung-Hsiang HsuHann-Chorng KuoDai-Wei LiuMoon-Sing LeeEn-Lin TsaiMing-Hsiang Chu
IMRT FOR A MALIGNANT MESOTHELIOMA/ Chi-Yuan YehPerng-An LaiKuang-Wei HuangChiu-Ping ChenJo-Ting Tsai
PROGNOSTIC FACTORS AFFECTING THE OUTCOME OF ENDOMETRIAL CANCER/ Chu-Ping PiMu-Tai LiuJui-Chang HsuChia-Chun HuangTung-Hao ChangAi-Yih WangWen-Shan LiuChao-Yuan Huang
時間因素對頭頸部癌症手術後放射治療的影響/ 蕭光吟張慶雄胡渝昌陳建勳蔡佩倩
 
   
 
   

與TAO合作 | 隱私與版權聲明 | 聯絡方式 | 下載Adobe Reader
地址:台北市中正區(100)北平東路30-12號3樓
電話:(02)2393-6968 傳真:(02)2393-6877
Email: service@wordpedia.com
Wordpedia Family: 學校、企業版入口 | 遠流影音館
Copyright©2011 Wordpedia Co., Ltd. All Rights Reserved.